Immutep narrows efti strategy as manufacturing clues reshape development path

Immutep has reset the development strategy for its lead immunotherapy eftilagimod alfa, or efti, concentrating future registration-directed work on two areas where management believes the clinical evidence and regulatory pathway are strongest.

The company now intends to focus on head and neck squamous cell carcinoma in patients with negative PD-L1 expression, defined as a Combined Positive Score below 1, and on efti in the neoadjuvant treatment of soft tissue sarcoma.

The narrowing follows the early discontinuation of the TACTI-004 study, an outcome that put both the clinical program and efti's manufacturing profile under considerable scrutiny. The important development for investors is that Immutep's investigation has so far identified differences between material manufactured at different production scales, while not finding clinical or trial execution factors that explain the unexpected result.

That is not the same as having a definitive explanation. The root cause analysis remains underway, and management has promised a further update once it is complete.

Manufacturing scale emerges as a key question

The investigation has identified structural differences between efti produced at the 200-litre scale and material manufactured at the 2,000-litre scale used exclusively in TACTI-004.

Among the differences identified is a subtle variation in N-glycan structure. Immutep considers this potentially relevant because TACTI-004 produced a markedly different immune activation profile from earlier studies and an unexpected clinical outcome.

The company has now contracted a fresh manufacturing run at the 200-litre scale. That scale has history behind it: 10 GMP batches were previously manufactured at 200 litres and used across successful Phase I and Phase II trials including TACTI-mel, TACTI-002 and INSIGHT-003.

For biotech investors, the distinction matters. Manufacturing consistency is not merely a factory-floor issue for biologic drugs. Changes in product characteristics can potentially affect biological activity, which makes resolving the scale-related differences important before Immutep commits substantial capital to another registration-directed study.

Management says the available evidence does not point to a suboptimal protocol, major treatment-arm imbalance, safety finding, invalid randomisation pattern or broader trial-conduct issue as the explanation for TACTI-004. That leaves manufacturing and pharmacological questions firmly under the microscope.

Head and neck cancer and sarcoma move to centre stage

The head and neck program will target patients with CPS below 1, a group characterised by limited approved treatment options and high unmet medical need. Immutep cites clinical efficacy data, including mature overall survival results, as support for pursuing this population.

Efti has also received Fast Track designation from the US Food and Drug Administration in first-line head and neck cancer. Management describes previous FDA feedback as constructive, adding regulatory weight to the decision to prioritise this setting.

The second priority is neoadjuvant soft tissue sarcoma. Here, Immutep is leaning on positive Phase II data that achieved its primary endpoint, together with Orphan Drug Designation granted by the FDA in April 2026.

The shift is therefore less about spreading efti across multiple tumour types and more about concentrating resources where the clinical signal, regulatory support and potential route to market appear most compelling.

Next trials targeted for the second half of 2027

Preparations for the next studies have begun, with Immutep targeting a start in the second half of calendar 2027.

That timetable comes with several caveats. Final trial design, regulatory discussions, manufacturing timelines, partnering arrangements and available resources all remain dependencies. The company specifically flags additional funding and the outcome of partnering discussions among the risks that could affect development.

Licensing partner Dr. Reddy's Laboratories has been consulted and supports the proposed approach. Immutep is also holding preliminary discussions with other parties regarding the development pathway, although no further detail has been provided.

Chief executive Marc Voigt said the company believes there remains "a scientifically and clinically justified path" for efti, pointing to evidence across multiple tumour types, immune activation data and encouraging results in sarcoma and CPS-negative head and neck cancer.

At the same time, Voigt acknowledged the significance of TACTI-004 and said the company intends to apply the lessons from its ongoing investigation "rigorously".

Investors now have a clearer set of milestones

The strategic reset gives investors a more concentrated list of issues to watch: completion of the root cause analysis, results from the new 200-litre manufacturing run, regulatory agreement on future trial design, funding and partnering progress, and whether the targeted 2027 clinical timetable remains achievable.

Meanwhile, Immutep's broader LAG-3 portfolio has not been shelved. Development of IMP761, its agonist anti-LAG-3 antibody targeting autoimmune disease, is continuing according to previously disclosed plans.

The immediate investment narrative, however, is squarely back on efti. The program has not returned to business as usual after TACTI-004. Instead, Immutep is taking a more selective route, with manufacturing comparability and regulatory alignment now just as important as the clinical data itself.